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Background: Alpha1-antitrypsin deficiency (AATD) is an underdiagnosed genetic disorder that
results in early-onset emphysema due to low serum levels of alpha1-proteinase inhibitor
(alpha1-PI), leading to increased activity of tissue-damaging neutrophil elastase. Clinical out-
comes of AATD may be improved by administering alpha1-PI augmentation therapy. Here, we
describe the design of the ongoing Study of ProlAstin-c Randomized Therapy with Alpha-1
augmentation (SPARTA), a phase 3 trial designed to evaluate progression of lung tissue loss
in patients with severe AATD receiving human alpha1-PI (Prolastin
-C) versus placebo, using
whole-lung computed tomography (CT) densitometry.
Study design: SPARTA is a randomized, placebo-controlled trial assessing the efficacy and
safety of two separate doses of Prolastin-C (60 and 120 mg/kg) administered weekly over 3
years in patients aged 18e70 years with a diagnosis of AATD and clinical evidence of pulmonary
emphysema. The primary measure of efficacy (change from baseline whole-lung 15th percen-
tile lung density [PD15]) will be determined by CT lung densitometry measured at total lung
capacity. Secondary efficacy variables will be the evaluation of severe chronic obstructive pul-
monary disease exacerbations, as defined by American Thoracic Society/European Respiratory
Society criteria, and PD15 of the basal lung region using CT densitometry. Adverse events will
be collected and documented.P.O. Box 110526, 4201 Research Commons, 79 T. W. Alexander Drive, Research Triangle Park, NC
1 919 641 1828 (mobile); fax: þ1 919 287 2939.
ols.com (S. Sorrells).
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Design of the SPARTA trial in AATD patients 491Conclusions: The SPARTA trial is designed to evaluate the long-term (3-year) efficacy of 2 sepa-
rate doses of Prolastin-C for the treatment of emphysema in patients with AATD.
Protocol number: GTi1201.
Clinical trials identifier: NCT01983241.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Alpha1-antitrypsin (AAT) deficiency (AATD) is a genetic
disease that results in emphysema and may occur in up to
3% of all patients with chronic obstructive pulmonary dis-
ease (COPD) [1e3]. This condition results from mutations in
the SERPINA1 gene encoding the serine protease inhibitor
alpha1-proteinase inhibitor (alpha1-PI), with PiS and PiZ
being the most commonly deficient alleles. Alpha1-PI in-
hibits the human neutrophil elastase, which, in large
quantities, can cause destruction of alveolar walls in the
lung [4,5]. AATD disrupts the protease-antiprotease bal-
ance, leading to an excess activity of elastase and, conse-
quently, tissue destruction. Inheritance of both PiZ alleles
reduces alpha1-PI serum levels to below the threshold level
(11 mM) required for adequate neutrophil elastase inhibition
[6,7], resulting in an increased risk for early onset of
emphysema, particularly in patients who smoke. The mean
age of diagnosis of AATD is 45.5 years, with 30.8% of pa-
tients being diagnosed over age 50 [3].
General principles to treat subjects with severe AAT
deficiency with emphysema include: 1) avoidance of res-
piratory irritant substances, especially tobacco smoke; 2)
supportive therapy, including medication (antibiotics,
bronchodilators, and corticosteroids), cardiovascular
conditioning and oxygen therapy, if clinically indicated; 3)
surgery, including lung transplants and lung volume
reduction surgery; and 4) treatment modalities targeting
the molecular basis of AAT deficiency, including inhibition
of polymerization of PiZZ or replacement of defective or
absent genes, although the major focus of treatment for
patients with emphysema due to severe AAT deficiency
has been on correcting the deficiency by means of
augmentation therapy [2,8,9,10]. Augmentation therapy
with exogenous alpha1-PI provides the opportunity for
targeted AATD therapy [11,12]. Crystal and colleagues
first tested the feasibility and safety of alpha1-PI
replacement therapy, suggesting that the most direct
approach to therapy for AATD would be to replenish the
missing protease inhibitor and thus re-establish the anti-
neutrophil elastase protection for the lower respiratory
tract [11]. Intravenous (IV) administration of Prolastin
(plasma-derived alpha1-PI [human]) has been shown to
increase serum levels of alpha1-PI, and on the basis of this
biochemical efficacy, Prolastin was the first alpha1-PI
approved for the treatment of patients with AATD [10].
Following its approval, other alpha1-PI preparations were
approved on the basis of bioequivalence to Prolastin, but
controlled trials to demonstrate clinical efficacy were not
conducted for any alpha1-PI augmentation therapy
[13,14].Since the development of Prolastin, manufacturing
processes have been modified to incorporate additional
purification and pathogen-reduction steps to formulate
Prolastin-C (alpha1-proteinase inhibitor [human]), which
has equivalent pharmacokinetics (PK) and a similar safety
profile to Prolastin [15,16]. Currently, Prolastin-C is
approved in the US, Canada, Colombia, and Argentina for
60 mg/kg weekly IV administration in patients with AATD
and clinically evident emphysema [2].
Findings from various studies have provided results sup-
porting the use of augmentation therapy in patients with
AATD; however, there is a lack of scientific consensus
regarding the clinical benefits of alpha1-PI administration.
Multiple retrospective and prospective studies have
demonstrated that alpha1-PI reduces lung function decline
as measured by forced expiratory volume in 1 s (FEV1),
especially in patients with moderate lung dysfunction
[17e19]. However, conflicting results from studies that have
failed to demonstrate preservation of lung function with
alpha1-PI augmentation therapy [8,19] suggest the need for
new studies and measures that can be used to accurately
evaluate COPD progression. The use of computed tomogra-
phy (CT) scans to evaluate the progression of emphysema-
tous lung tissue has been evaluated in several studies (Table
1). An observational non-randomized study from the Na-
tional Heart, Lung, and Blood Institute (NHLBI) Alpha1-
Antitrypsin Deficiency Registry (ClinicalTrials.gov Identi-
fier: NCT00005292) of 1129 subjects revealed a reduced risk
of mortality in patients with AATD receiving augmentation
therapy compared with those receiving no therapy
[17,20,21]. Lung density measurements by CT scan have
been shown to be a sensitive measure for assessing emphy-
sema progression and as an outcome measure of
emphysema-modifying therapy in patients with AATD
[22,23]. The use of radiologic assessments as the primary
efficacy endpoint is attractive in an orphan disease such as
AATD where large numbers of patients would be required to
demonstrate differences in more variable endpoints such as
FEV1 and pulmonary exacerbations. In November 2007, a
draft guidance was published by the US Food and Drug
Administration supporting the use of sensitive radiologic
assessments as primary efficacy endpoints in COPD trials
[24]. However, randomized, controlled clinical trials
demonstrating the validity of CT endpoints in demonstrating
the efficacy of alpha1-PI products have not yet been done.
The Study of ProlAstin-c Randomized Therapy with
Alpha-1 augmentation (SPARTA) trial has been designed to
fulfill the request by health authorities for conclusive data
demonstrating the clinical efficacy of alpha1-PI augmenta-
tion therapy for AATD-induced emphysema. To date, no
dose-ranging studies have been conducted with any alpha1-
Table 1 Characteristics of clinical trials to evaluate treatment with alpha1-PI formulations in patients with AATD.
Seersholm
et al. [19]
NHLBI AATD
Registry Study
Group [17]
Wencker et al.
[18]
Dirksen et al.
[25]
Wencker et al.
[26]
EXACTLE [23] ChAMP [15] SPARK [27] SPARTA RAPID [28]
Year 1997 1998 1998 1999 2001 2009 2010 2013 2013 2014
Study design Prospective,
multicenter,
controlled,
nonrandomized
Prospective,
multicenter,
nonrandomized,
Prospective,
long-term,
multicenter,
nonrandomized
Prospective,
randomized,
parallel,
double-blind,
placebo-
controlled trial
at 2 centers
Multicenter,
retrospective
cohort
Prospective,
randomized,
double-blind,
placebo-
controlled,
parallel group
Prospective,
multicenter,
randomized,
double-blind,
crossover
Prospective,
multicenter,
randomized,
double-
blind,
crossover
Prospective,
randomized,
double-blind,
placebo-
controlled,
parallel group
Prospective,
randomized,
double-
blind,
placebo-
controlled,
parallel
group
Number of
patients
295 927 287 56 96 77 24 30 339 180
Experimental
drug dosage
and regimen
Prolastin
60 mg/kg
weekly
Alpha-1 protease
inhibitor
formulation
60 mg/kg weekly
Prolastin
60 mg/kg
weekly
Alpha-1
protease
inhibitor
formulation
250 mg/kg at 4-
wk intervals
Prolastin
60 mg/kg
weekly
Prolastin-C
60 mg/kg
weekly
Prolastin-C
60 mg/kg
weekly
Prolastin-C
120 mg/kg
weekly
Prolastin-C
120 mg/kg
weekly
Zemaira
60 mg/kg
weekly
Comparator No
augmentation
therapy
No augmentation
therapy
N/A Albumin
(625 mg/kg) at
4-wk intervals
N/A Placebo Prolastin
60 mg/kg
weekly
Prolastin-C
60 mg/kg
weekly
Prolastin-C
60 mg/kg
weekly and
placebo
Placebo
Primary
efficacy
parameter
Annual change
in FEV1
Decline in FEV1
and mortality in
relation to
augmentation
therapy
Annual decline
in FEV1
Annual decline
in FEV1
Annual decline
in FEV1
Change in the
15th percentile
lung density
AUC0e7 days
postdose
AUC0e7 days,
Cmax,
elimination
rate, t1/2,
tmax, Ctrough
Change in the
15th percentile
lung density
Change in
the 15th
percentile
lung density
Secondary
efficacy
parameter
Annual change
in FEV1 by
gender, follow-
up time, and
initial FEV1%
pred
N/A N/A 15th percentile
point of the
lung density
distribution of
the whole lung
measured by
CT scanning
N/A Lung function,
frequency of
exacerbations,
and health
status St.
George’s
Respiratory
Questionnaire
Cmax, tmax,
Ctrough
N/A Severe COPD
exacerbations,
basal lung CT
densitometry
Spirometry,
KCO, shuttle
walk
492
S.
So
rre
lls
e
t
a
l.
Study findings Slower decline
in FEV1 in
treated vs
untreated
group
(p Z 0.02) No
difference
when stratified
by gender
(p Z 0.64) or
follow-up
(p Z 0.46).
Slower FEV1
pred decline in
pts with FEV1%
pred 31e65%
Slower decline in
FEV1 in treated
patients with
moderately
decreased lung
function
(p Z 0.03);
Decreased
mortality in
patients
receiving
therapy
(p Z 0.02)
The rate of
decline in FEV1
in these
treated
patients
(w57 mL/y)
was
approximately
half that
reported
(historical
data) for
untreated
controls
No difference
in FEV1.
Reduced
decline of lung
tissue
(p Z 0.07)
Slower decline
in FEV1 during
treatment
period vs
pretreatment
period for
entire group
(p Z 0.019)
CT more
sensitive
measure of
emphysema-
modifying
therapy than
physiology and
health status,
and
demonstrates a
trend of
Prolastin-C
treatment
benefit
PK paramaters
of Prolastin-C
are equivalent
to Prolastin
Prolastin-C
(120 mg/kg)
weekly was
well
tolerated
and
provided
more
physiologic
alpha1-PI
levels than
Prolastin-C
(60 mg/kg)
N/A 34%
reduction in
lung density
decline in
patients
receiving
alpha1-PI
60 mg/kg IV
compared
with
placebo.
Secondary
outcome
measures
were not
statistically
significant
between
treatment
groups
AATD alpha1-antitrypsin deficiency, AE adverse event, Alpha1-PI alpha1-proteinase inhibitor, AUC area under the curve, ChAMP Comparability pharmacokinetics of Alpha-1 Modified
Process, Cmax maximum plasma concentration, Ctrough lowest concentration prior to administration of next dose, CT computed tomography, EXACTLE Alpha-1-Antitrypsin (AAT) To Treat
Emphysema In AAT-Deficient Patients, FEV1 forced expiratory volume in 1 s, KCO Association of the transfer coefficient, N/A not applicable, NHLBI National Heart, Lung, and Blood
Institute, PK pharmacokinetics, Pred predicted, SPARK Safety and Pharmacokinetics of Alpha-1 proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency, SPARTA Study of
ProlAstin-c Randomized Therapy with Alpha-1 augmentation, t1/2 half-life, tmax time to maximum plasma concentration.
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494 S. Sorrells et al.PI product. The current standard dose was determined
based on the fact that a dose of 60 mg/kg weekly main-
tained serum levels above the putative protective threshold
of 11 uM [10]. However, since this serum level is still below
the normal range of alpha1-PI serum levels in healthy pa-
tients (20e53 uM) [6], there has been an interest in eval-
uating the efficacy of higher doses of alpha1-PI. Therefore,
the SPARTA study has been designed to include a higher
dose of Prolastin-C of 120 mg/kg weekly. Prior to initiating
SPARTA, the Safety and PhARmacoKinetic (SPARK) trial, a
multicenter, randomized, double-blind, crossover study,
was conducted to ensure that the safety and pharmacoki-
netics (elimination rate constant and t1/2) of weekly in-
fusions of Prolastin-C 120 mg/kg were similar compared
with the 60 mg/kg weekly dose. The results of SPARK
demonstrated that 120 mg/kg Prolastin-C weekly was well
tolerated and conferred higher serum levels of alpha1-PI
(27.7 uM) compared with 60 mg/kg (17.3 uM) in patients
with AATD [27]. SPARTA is a randomized, double-blind,
placebo-controlled trial assessing the effects of two sepa-
rate doses (60 and 120 mg/kg) weekly of Prolastin-C on
emphysema progression over three years.Study design
SPARTA is a multicenter, randomized, double-blind, pla-
cebo-controlled, phase 3 clinical trial (protocol number:
GTi1201, clinicaltrials.gov identifier: NCT01983241)
designed to evaluate two dose regimens (60 and 120 mg/kg)
of Prolastin-C versus placebo (0.9% sodium chloride for in-
jection, USP). During the 21-day screening phase, patients
will be assessed for study eligibility and will receive a
baseline CT scan. At the baseline visit, eligible patients
(N Z 339) will be randomized 1:1:1 to receive weekly IV
infusions of Prolastin-C 60 mg/kg, Prolastin-C 120 mg/kg, or
placebo. Randomization will be stratified by the baseline
forced expiratory volume in 1 s (FEV1; 30%e<35%, 35%e
60%, and >60%e<80%) with patients in each stratumFigure 1 Study design. CT computed tomography, IP investiga
performed anytime during the screening phase but must be comple
the baseline (week 1) visit.randomized to one of the three treatments to ensure
balanced assignment. Patients will receive weekly treat-
ments according to their assigned treatment group for 156
weeks (treatment phase). Computed tomography scans will
be performed at screening (baseline CT scan) and at weeks
52, 104, 130, and 156 of the treatment phase (Fig. 1). Pa-
tient participation will conclude after completing the end-
of-study visit at week 160. All of the study procedures will
be conducted within International Conference on Harmo-
nization Good Clinical Practice guidelines.Study population
Eligible patients for study inclusion are to be 18e70 years
of age, have a documented total alpha1-PI serum level
<11 mM, and have a diagnosis of congenital AATD with an
allelic combination of PiZZ, PiSZ, PiZ(null), Pi(null)(null),
PiS(null), or at-risk alleles as determined by the medical
monitor. To ensure all patients have emphysema, patients
must meet one of 2 criteria: 1) have a carbon monoxide
diffusing capacity (DLco) 60% of the predicted value
(corrected for hemoglobin) within the previous two years;
or 2) show evidence of emphysema on CT scan within the
previous two years per the investigator’s judgment. This
criterion in combination with the required FEV1 of 30%
and <80% of predicted and a reduced serum level of AAT
along with a documented deficiency allelic combination
will ensure a study population with obstructive lung dis-
ease. The inclusion and exclusion criteria are listed in
Table 2.Treatments
Patients included in the study will receive a total of 156
blinded IV infusions of Prolastin-C (60 mg/kg or 120 mg/kg)
or placebo, administered on a weekly schedule. Infusions
will be conducted at investigators’ study sites, ambulatorytional product, IV intravenous MP modified protein. aCan be
ted, reviewed, and approved by the central CT vendor prior to
Table 2 SPARTA key inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
1. Documented total alpha1-PI serum level
<11 mM
2. Diagnosis of congenital AATD with an allelic
combination of PiZZ, PiSZ, PiZ(null),
Pi(null)(null), PiS(null), or at-risk allelesa
3. At screening week 3, a postbronchodilator
FEV1 30% and <80% of the predicted value
and a FEV1/forced vital capacity <70%
(Global Initiative for Chronic Obstructive
Lung Disease stage 2 or 3) [29]
4. DLCO  60% of the predicted value (cor-
rected for HgB) within the past 2 years or
evidence of emphysema on the CT scan
within the past 2 years based on the judg-
ment of the investigator
5. Clinical evidence of emphysema per the in-
vestigator’s judgment
1. Has received alpha1-PI augmentation therapy for >1 month within
the 6 months prior to screening
2. Has received alpha1-PI augmentation therapy within 1 month of
screening
3. Has experienced a COPD exacerbation within the 5 weeks prior to
screening or during the screening phaseb
4. Unable to physically (eg, unable to fit inside the CT scanner) or
mentally (eg, claustrophobic) undergo a CT scan
5. A history of lung or liver transplant
6. Any lung surgery during the prior 2 years (excluding lung biopsy)
7. On the waiting list for lung surgery, including lung transplant
8. Smoking during the past 12 months or a positive urine cotinine test at
screening due to smoking
9. History of anaphylaxis or severe systemic response to any plasma-
derived alpha1-PI preparation or other blood product(s)
10. Use of systemic steroids above a stable dose equivalent to 5 mg/day
prednisone within the 5 weeks prior to screening or during the
screening phasec,d
11. Use of systemic or aerosolized antibiotics for a COPD exacerbation
within the 5 weeks prior to screening or during the screening phased
12. Known selective or severe immunoglobulin A deficiency
AATD alpha1-antitrypsin deficiency, BMI body mass index, CT computed tomography, DLCO carbon monoxide diffusing capacity, HgB
hemoglobin.
a Patients with at-risk alleles will be evaluated individually by the medical monitor. In cases of no documented genotype, genotyping
(allelic discrimination) and phenotyping will be performed at the time of screening (week -3).
b In cases of a patient who has had a COPD exacerbation more than 5 weeks prior to screening but is otherwise appropriate for study
participation, investigator discretion should be followed.
c Inhaled steroids are not considered systemic steroids; it is recommended that the same dose be maintained throughout the study.
d Patients were excluded because administration was indicative of a recent COPD exacerbation.
Figure 2 Infusion bag blinding. aThe total placebo (0.9%
Sodium Chloride for Injection) volume will be calculated based
on the 120 mg/kg dose.
Design of the SPARTA trial in AATD patients 495infusion centers, local healthcare professionals’ sites, or a
home location via a local healthcare professional or agency.
Each week, an unblinded pharmacist or designee will pre-
pare two blinded IV bags (infusion bag 1 and infusion bag 2)
to account for the difference in volume between the
60 mg/kg and the 120 mg/kg doses (Fig. 2). Blinding of the
three treatment groups will be guaranteed by ensuring all
patients receive the same total volume for all treatment
groups with no visible differences in external aspects of the
treatment groups. Patients who miss 10 or more infusions in
a year or more than four consecutive weekly infusions will
be considered noncompliant and will be withdrawn from
the study.
Use of any other alpha1-PI augmentation therapy or any
investigational product will not be permitted during the
conduct of the study.
Efficacy variables
The primary efficacy variable is the change from baseline in
whole-lung 15th percentile lung density (PD15) at total lung
capacity (TLC) using CT densitometry. Whole-lung CT scans
will be performed by technicians who have undergone
certification by a central CT vendor. The CT scan data ob-
tained at each study site will be sent to the central CT
vendor for review and analysis in a blinded manner, and this
data will be used to evaluate efficacy. It is required that the
baseline CT scan obtained during the screening phase be
496 S. Sorrells et al.completed, reviewed, and approved by the central CT
vendor prior to the baseline visit to ensure the patients
have emphysema, according to the inclusion criteria. The
CT scans conducted during the treatment phase should be
performed within 30 days of the scheduled CT visit.
Within 15 min to 4 h prior to performing each CT scan, each
patient will be administered an inhaled, short-acting
bronchodilator (eg, albuterol). Each patient should have
all protocol-specified CT scans performed using a same
scanner during the study.
Secondary efficacy variables include the incidence of
severe COPD exacerbations as defined by American Thoracic
Society (ATS)/European Respiratory Society (ERS) [30]1
criteria and basal lung CT densitometry (PD15). Exploratory
variables will be the following: incidence and severity of
COPD exacerbations as defined by ATS/ERS criteria, change
from baseline in FEV1, health-related quality of life as
measured by the St. George’s Respiratory Questionnaire
(SGRQ), and assessment of other CT scan parameters (to be
determined upon study completion).
Safety variables
Adverse events (AEs) and concomitant medication use will
be assessed during the study from screening through week
160/early discontinuation visit. The safety variables eval-
uated will be adverse events (AEs), serious AEs (SAEs), and
discontinuations due to AEs and SAEs. Physical examina-
tions (complete and respiratory) will be conducted, and
clinical laboratory parameters, including determination of
high-sensitivity C-reactive protein and Prolastin-C immu-
nogenicity, will also be assessed. For immunogenicity
testing, blood samples drawn at baseline, week 13, and
week 52 will be assayed for antibodies against Prolastin-C.
Samples with a positive test result based on both screening
and confirmatory assays will subsequently be tested for
neutralizing antibodies and the antibody titer. Patients will
be withdrawn from the study if they experience a decline in
FEV1 at a rate of 134.4 mL/year at or after week 104.
Follow-up
Any patients who receive investigational product and dis-
continue early from the study will be requested to return
for early discontinuation visit procedures as close as
possible to 28 days after their last treatment administra-
tion. In addition, all patients who complete all three years
of the SPARTA trial as well as those patients who are
withdrawn specifically due to meeting the FEV1 rate decline
will be eligible to enroll into a subsequent two-year, open-
label study.1 Mild: involves an increase in one or more respiratory symptoms
(dyspnea, cough, and/or sputum) that is controlled by the subject
with an increase in the usual medication. Moderate: requires
treatment with systemic steroids and/or antibiotics. Severe: de-
scribes exacerbations that require hospitalization (Note: For the
purpose of this protocol, an emergency department stay >24 h is
considered a hospitalization).Statistical considerations
Study populations
Efficacy analyses will be performed on the intent-to-treat
(ITT) population, which will consist of all patients who are
randomized. The primary efficacy analyses of the CT scan
data will be based on the modified ITT (mITT) population,
which will consist of all patients in the ITT population with
a valid baseline and at least 1 valid postbaseline CT scan
measurement. The safety population will comprise all
randomized patients who receive at least 1 infusion of
study treatment. The per-protocol population will consist
of all randomized patients who fulfill all entry criteria, have
80% treatment compliance, a valid baseline CT scan and
1 valid postbaseline CT assessment, and a randomization
code that was not broken by the investigator.
Efficacy analyses
For the primary efficacy analysis, a random coefficient
regression model will be used to compare the 60 mg/kg or
120 mg/kg dose of Prolastin-C to placebo. The model will
include TLC-adjusted lung density as the dependent vari-
able and treatment, center/region, and treatment-by-time
interaction as fixed effects and intercept and time as
random effects. The Hochberg procedure will be used to
control the experiment-wise alpha level at 0.05. As a
sensitivity analysis, change from baseline of the TLC-
adjusted lung density to endpoint will be analyzed using
analysis of covariance (ANCOVA) for the comparison of the
two active treatment groups vs placebo. Other efficacy
variables will be analyzed by a random coefficient regres-
sion model and ANCOVA for PD15 of basal lung region using
CT densitometry, other CT scan parameters, FEV1, and
SGRQ. The incidence of exacerbations will be analyzed
using a Poisson regression model with treatment and cen-
ter/region as fixed effects and the duration in the study as
an offset variable. The annual COPD exacerbation rates will
also be analyzed using analysis of variance (ANOVA) with
treatment and center/region as fixed effects.
Safety analysis
The documented AEs, SAEs, drug-related AEs, AEs by
severity, and laboratory tests will be summarized using
descriptive statistics. Deaths, SAEs, and AEs leading to
premature discontinuation from the study will be listed. For
all laboratory tests, the original value and the change from
baseline will be summarized for numeric results and the
frequency/percentage will be summarized for qualitative
results. The results of physical/respiratory examinations
will also be presented.
Determination of sample size
The number of patients needed in each treatment arm was
estimated based on Schluchter et al. [21], together with
simulations using data from the Alpha-1-Antitrypsin (AAT)
To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
Design of the SPARTA trial in AATD patients 497trial [23]. Based on the change from baseline PD15 as the
primary endpoint analyzed using ANCOVA for a 3-year trial,
it was determined that 75 patients per arm would achieve
at least 80% power for an alpha level of 0.05 with a treat-
ment effect size of 0.7 g/L per year with between-subject
variation of 0.6 g/L and within-patient variation of 2.3 g/L.
For multiplicity adjustment using the Hochberg procedure,
90 patients per arm will be needed to achieve 80% power
for an alpha level of 0.025. Based on 90 patients per arm
and considering a 20% dropout rate, the enrollment goal for
SPARTA is 113 patients in each arm.Discussion
Optimization of the treatment of patients with AATD has
been hindered by difficulties associated with a disease that
is relatively uncommon, thus there is a limited number of
patients available for study purposes. Furthermore, there is
uncertainty regarding the most appropriate clinical
outcome measure of emphysema progression in clinical
trials. FEV1 is the “gold standard” clinical measure of COPD
progression [23]. Although measurement of FEV1 is easy to
perform and well established, study estimates indicate that
the detection of differences in FEV1 decline over a 3-to-5-
year period would require a large number of patients due
to the slow progression of AATD. In addition, FEV1 does not
provide information about lung tissue loss, but about the
resultant change in lung function [30]. DLco has also been
used extensively to evaluate COPD progression, however,
there is a lack of uniformity in its assessment of disease
progression across the spectrum of disease severity [31].
Chronic obstructive pulmonary disease exacerbations are
important clinical manifestations of COPD due to AATD and
they are frequently evaluated in clinical trials. However,
they are subjective and there is no validated tool to allow a
standardized method of defining the start and end of an
exacerbation or the severity of the exacerbation [31]. Thus,
long-term trials that incorporate sensitive and objective
measures of changes in lung structure are needed to eval-
uate the efficacy of alpha1-PI augmentation therapy in
patients with AATD.
Computed tomography scan densitometry has been
shown to be a sensitive measure of changes in the archi-
tecture of the lung. Dirksen et al., published results sup-
porting the use of CT scans for lung density measurements
in patients with AATD [25]. Subsequently, the EXACTLE
(ClinicalTrials.gov Identifier NCT00263887) trial, a two-
year, multicenter, randomized, exploratory trial, was con-
ducted to assess the frequency of exacerbations and the
progression of emphysema using multislice CT scans in pa-
tients with AATD receiving Prolastin 60 mg/kg. The results
of EXACTLE showed that CT is a more sensitive outcome
measure of emphysema-modifying therapy than physiology
and health status and demonstrated a trend toward a
treatment benefit of augmentation therapy [23]. The
multinational, Randomized, placebo-controlled trial in
Alpha-1 Proteinase Inhibitor Deficiency (RAPID) used CT
densitometry to evaluate the effects of the alpha1-PI
Zemaira (CSL Behring, King of Prussia, PA) on the pro-
gression of lung tissue loss over two years. Investigators
reported a 34% reduction in lung density decline evaluatedby PD15 at TLC in patients receiving alpha1-PI 60 mg/kg IV
compared with placebo. These results suggest that alpha1-
PI augmentation therapy can reduce lung tissue decline,
and provide additional evidence that CT densitometry can
effectively measure lung tissue loss in patients with
emphysema [23]. However, CT densitometry is a relatively
recent entrant into the study of COPD progression and cli-
nicians may lack familiarity, which could complicate study
interpretation [22]. Increased use of CT densitometry in
clinical trials as well as the clinical setting could overcome
this barrier.
The results of the SPARK study, which provided the PK
and safety rationale for evaluating a higher dose, demon-
strated that an increased weekly dose of 120 mg/kg
Prolastin-C in patients with AATD was well tolerated and
safe. This higher dose resulted in a mean steady state
trough of alpha1-PI (27.7 mM), which is within the normal
range of alpha1-PI serum levels in healthy patients
(20e53 mM). In contrast, the standard dose of 60 mg/kg
Prolastin-C weekly provided a mean steady state trough of
17.3 mM, consistent with serum levels of alpha1-PI that are
greater than the protective threshold of 11 mM but still
lower than the levels of individuals without AATD with
normal serum alpha1-PI levels [27]. The achievement of
nondeficient levels of alpha1-PI may decelerate the rate of
lung tissue damage that occurs in patients with AATD, thus
reducing the lung function decline and improving patient
quality of life. The results of SPARK provided the basis for
the dose regimens selected for the SPARTA trial.Conclusions
In comparison with previous clinical trials investigating the
treatment of patients with AATD, SPARTA is distinguished by
a number of important features. The SPARTA trial is
placebo-controlled and incorporates two doses of Prolastin-
C administered weekly (60 mg/kg or 120 mg/kg). These two
dose regimens of Prolastin-C will be administered to
enrolled patients for a duration of three years, which ex-
ceeds by at least one year the study periods used in pre-
vious trials examining the effects of alpha1-PI
administration. Furthermore, the established outcome as-
sessments of pulmonary function based on lung architec-
ture will be evaluated by a CT scan at total lung capacity as
well as a basal CT scan to evaluate the lower lobes of the
lung, which are typically affected by AATD-associated
emphysema. Pulmonary function will also be assessed by
spirometry measures performed at a central laboratory.
Collectively, these features of SPARTA are anticipated to
provide much-needed, robust results to demonstrate the
efficacy of Prolastin-C augmentation therapy in patients
with AATD.
The results of SPARTA are intended to provide data
demonstrating a slowed progression of emphysematous lung
disease in patients with AATD receiving weekly infusions of
Prolastin-C augmentation therapy. This study will also
assess whether there is incremental clinical benefit from a
dose (120 mg/kg) that increases alpha1-PI levels to within
the normal range of healthy individuals. Furthermore,
these results are anticipated to help underscore the
498 S. Sorrells et al.importance of augmentation therapy in the treatment of
patients suffering from this condition.
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